"Ulcosilvanil"--an inhibitor of carbonic anhydrase--associated with adrenergic beta-blockers in the treatment of duodenal ulcers.
Knowing the in vivo inhibitory effect of the beta-adrenoreceptor antagonists on gastric mucosa carbonic anhydrase and the high clinical efficacy of "Ulcosilvanil" in the healing of gastric and duodenal ulcers, the authors combined propranolol with smaller doses of "Ulcosilvanil" in 925 active duodenal ulcer patients, divided into four groups. The first 236 patients were treated with small doses of "Ulcosilvanil" (20 mg/kg b.w./day active substance), the second group (of 258 cases) with high doses (35 mg/kg b.w./day) of "Ulcosilvanil", the third one (182 subjects) with propranolol only (60 mg/day) and the fourth group (349 patients) with small doses of "Ulcosilvanil" associated with 60 mg/day propranolol. Pain disappeared in all the cases of groups 1,2 and 4 after 3-6 days of treatment and in 40% of the third group. Basal acid output decreased, after 10 days of treatment, from 6.15 +/- 1.57 to 1.94 +/- 0.66 mEq/h in the first group (p less than 0.001), from 7.98 +/- 2.34 to 0.01 +/- 0.01 mEq/h in the second group (p less than 0.001), from 6.43 +/- 2.45 to 2.09 +/- 0.50 mEq/h in the third group (p less than 0.02) and from 6.76 +/- 2.80 to 0.011 +/- 0.01 mEq/h in the fourth group (p less than 0.001). Endoscopic healing was achieved, after 14 days of treatment, respectively in 78.5%, 92.4%, 51.6% and 88.41%; this percentages increased to 82.3%, 96.8%, 68.1% and 93.5% after 21 day of treatment.(ABSTRACT TRUNCATED AT 250 WORDS)